Actively Recruiting
Azithromycin for Child Survival in Niger II
Led by University of California, San Francisco · Updated on 2025-06-22
3300000
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
C
Centre de recherche et interventions en santé publique (CRISP)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.
CONDITIONS
Official Title
Azithromycin for Child Survival in Niger II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Located in a region participating in the program
- Designated as rural by local study team
- Selected for participation in monitoring activities
- Safe and accessible for study teams
- Verbal approval from community leaders
- Residing in the catchment area of an eligible CSI
- Selected for participation in monitoring activities
- Female aged between 12 and 55 years old
- Verbal approval from participant
- Residing in the catchment area of an eligible CSI
- Selected for participation in monitoring activities
- Child aged between 1 and 59 months old
- Verbal approval from a caregiver or guardian
You will not qualify if you...
- Designated as urban by local study team
- Inaccessible or unsafe for study team
- Known allergy to macrolides
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Program National de Santé Oculaire
Niamey, Niger
Actively Recruiting
Research Team
A
Andrea R Picariello, MPH
CONTACT
E
Elodie Lebas
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here